CD47 and prostate carcinoma: Furthermore, the susceptibility of cancer cells to taxane-based chemotherapy can be enhanced by either silencing TXR1 with small interfering RNA or by stimulating CD47 (also referred to as IAP, for integrin-associated protein) through TSP-1 or a TSP-1 peptide mimic in human prostate cancer cell lines (Lih et al., 2006).